Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556764 · ClinicalTrials.gov registry record · Early Phase 1
Development of Cognitive Assessment Tools in Parkinson Disease
A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 75
- Enrollment target
NCT00556764: Completed Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00556764 is a Early Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 75 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00556764, a Early Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparisons to available standardized cognitive evaluation scales administered to the patients with Parkinson disease with and healthy control subjects. 3. To evaluate the reliability of the ANAM-PD battery of tests by comparing repeated administrations of the ANAM-PD battery on a sub-set of subjects with Parkinson disease and healthy controls. 4. To characterize cholinergic neurotransmission through imaging the vesicular acetylcholine transporter binding with 123Iodobenzovesamicol (IBVM) and SPECT in PD patients and healthy controls.
Interventions
- DRUG [123I] IBVM and SPECT imaging
- DRUG Subjects will undergo the 123-I IBVM imaging visit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-03 |
| Phase | Early Phase 1 |
What the finished NCT00556764 record still lists
NCT00556764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 2 interventions - of which [123I] IBVM and SPECT imaging is the first listed.
NCT00556764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00556764 about?
NCT00556764 is a clinical study titled "Development of Cognitive Assessment Tools in Parkinson Disease". The main objectives of this protocol are as follows: 1. To assess the sensitivity and specificity of ANAM-PD in detecting cognitive status in patients with Parkinson disease (PD) and healthy controls (HC). 2. To validate the specific individual domains of the ANAM-PD cognitive battery by comparison...
What is the current status of trial NCT00556764?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 75 participants. The study started on 2007-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00556764?
The interventions under investigation include: [123I] IBVM and SPECT imaging (DRUG), Subjects will undergo the 123-I IBVM imaging visit (DRUG).
Who is sponsoring clinical trial NCT00556764?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00556764's enrollment target sits among peer trials
75 304th of 2000 higher than 1,690 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia